Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-concept Trial With Safety Run of Tepotinib and Pembrolizumab in NSCLC Patients With and Without MET Exon 14 Mutations (POTENT)

NCT05782361 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT05782361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05782361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-concept Trial With Safety Run of Tepotinib and Pembrolizumab in NSCLC Patients With and Without MET Exon 14 Mutations (POTENT)
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 3, 2023
Completion date
January 9, 2029
Enrollment
19 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, non small cell lung cancer